To ask the Secretary of State for Health and Social Care, whether he plans to make difluoromethylornithine available on the NHS for children with high-risk neuroblastoma.
We understand how important it is that cancer patients are able to benefit from rapid access to effective new treatments. We are aware that the manufacturer difluoromethylornithine (DFMO) has applied for a United Kingdom marketing authorisation through Pr...
Neuroblastoma: Drugs